Strona główna・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

26.07 1.01

Buy Sell

Overview

Share price change

24h

Current

Min

25.82

Max

26.22

Key metrics
By Trading Economics
Income	26M 15M
Sales	24M 130M
P/E Sector Avg	112.696 57.002
EPS	0.11
Profit margin	11.558
Employees	354
EBITDA	23M 17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+39.63% upside

Dividends
By Acuity
Next Earnings	27 paź 2026

Market Stats
By TradingEconomics
Market Cap	13M 3.3B
Previous open	25.06
Previous close	26.07

News Sentiment

By Acuity

50%

142 / 340 Ranking in Healthcare

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13 sie 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12 sie 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11 sie 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10 sie 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7 sie 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6 sie 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5 sie 2026, 23:02 UTC

News

Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4 sie 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3 sie 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31 lip 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30 lip 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29 lip 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28 lip 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27 lip 2026, 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24 lip 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

21 lip 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

20 lip 2026, 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

39.63% upside

12 Months Forecast

Average 36.57 USD 39.63%

High 40 USD

Low 34 USD

Based on 7 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

142 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.